

A sensitive and affordable multiplex RT-qPCR assay for SARS-CoV-2 detection

Martin A.M. Reijns^{1,*}, Louise Thompson², Juan Carlos Acosta³, Holly A. Black^{2,4}, Francisco J. Sanchez-Luque^{1,5}, Austin Diamond², Alison Daniels⁶, Marie O'Shea⁷, Carolina Ugenti⁴, Maria C. Sanchez, Michelle L.L. McNab⁶, Martyna Adamowicz⁴, Elias T. Friman¹, Toby Hurd¹, Edward J. Jarman¹, Frederic Li Mow Chee³, Jacqueline K. Rainger¹, Marion Walker³, Camilla Drake¹, Dasa Longman¹, Christine Mordstein^{1,8}, Sophie J. Warlow⁴, Stewart McKay¹, Louise Slater², Morad Ansari², Ian P.M. Tomlinson³, David Moore², Nadine Wilkinson⁹, Jill Shepherd⁹, Kate Templeton⁹, Ingolfur Johannessen⁹, Christine Tait-Burkard⁷, Jürgen G. Haas⁶, Nick Gilbert¹, Ian R. Adams¹, Andrew P. Jackson¹

1. MRC Human Genetics Unit, Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, UK
2. NHS Lothian, The South East of Scotland Clinical Genetic Service, Western General Hospital, Edinburgh, UK
3. Cancer Research UK Edinburgh Centre, Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, UK
4. Centre for Genomic & Experimental Medicine, Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, UK
5. Centre Pfizer-University of Granada-Andalusian Government for Genomics and Oncological Research (Genyo), Granada, Spain
6. Division of Infection Medicine, Edinburgh Medical School, University of Edinburgh, Edinburgh, UK
7. The Roslin Institute and Royal (Dick) School of Veterinary Studies, University of Edinburgh, Edinburgh, UK
8. The Milner Centre for Evolution, Department of Biology and Biochemistry, University of Bath, Bath, UK
9. NHS Lothian, Medical Microbiology and Virology Service, Royal Infirmary of Edinburgh, Edinburgh UK

* Correspondence to MAMR, martin.reijns@igmm.ed.ac.uk

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

1 **Abstract**

2 With the ongoing COVID-19 pandemic, caused by the novel coronavirus SARS-CoV-2, there is need
3 for sensitive, specific and affordable diagnostic tests to identify infected individuals, not all of whom
4 are symptomatic. The most sensitive test involves the detection of viral RNA using RT-qPCR, with
5 many commercial kits now available for this purpose. However, these are expensive and supply of
6 such kits in sufficient numbers cannot always be guaranteed. We therefore developed a multiplex
7 assay using well-established SARS-CoV-2 targets alongside internal controls that monitor sample
8 quality and nucleic acid extraction efficiency. Here, we establish that this test performs as well as
9 widely used commercial assays, but at substantially reduced cost. Furthermore, we demonstrate
10 >1,000-fold variability in material routinely collected by nose-and-throat swabbing. The inclusion of
11 a human control probe in our assay provides additional information that could help reduce false
12 negative rates.

13 Introduction

14 The COVID-19 pandemic originated in Wuhan (China) in December 2019 and at the time of writing
15 has infected more than 13.1 million people worldwide, resulting in well over 0.57 million COVID-19-
16 related deaths. In many countries the number of active cases is now declining, largely due to
17 increased public awareness and effective public health strategies centred on reducing the rate of
18 transmission. However, the number of cases worldwide is still on the increase with around 100,000
19 new cases recorded every day at the beginning of June and more than 200,000 new daily cases since
20 the beginning of July. Many of these new infections are now occurring in lower-middle-income
21 countries. Also, as lockdown measures are widely being eased there is an increased risk of a
22 renewed rise in infection rates, as evidenced by current trends observed in e.g. Iran and the USA.
23 Therefore, effective and affordable testing strategies to enable effective and widespread population
24 surveillance will continue to be important. The most sensitive test to diagnose infected individuals
25 involves the detection of SARS-CoV-2 viral RNA using RT-qPCR, most commonly using samples
26 collected using nasopharyngeal (nose-and-throat) swabs, although there is increasing evidence that
27 the use of saliva may be a valid alternative [1]. Many commercial kits are now available, most of
28 which employ multiplex RT-qPCR detecting 2 or 3 different SARS-CoV-2 targets, and generally
29 include an internal control to show successful nucleic acid extraction. However, such kits are often
30 costly and their supply in sufficient numbers cannot always be guaranteed. We therefore developed
31 a similar multiplex assay using well-established SARS-CoV-2 targets and internal controls, which can
32 be carried out at a significantly lower cost and provides more flexibility to ensure resilience against
33 potential shortages in reagent supplies.

34 Our assay makes use of the Takara One Step PrimeScript III RT-qPCR kit. This reagent was used in the
35 first high profile publication to describe the novel coronavirus 2019-nCoV [2], also referred to as
36 SARS-CoV-2, which causes COVID-19. It has since been shown to outperform a number of other
37 similar reagents [3]. Before commercial COVID-19 assays were available, a number of in-house

38 assays were published on the WHO website [4]. Based on the data available at the time, we decided
39 to focus our initial efforts on targeting the following SARS-CoV-2 genes: E (envelope), RdRp (RNA-
40 dependent RNA polymerase) and N (nucleocapsid) [5, 6]. Corman et al (2020) proposed the E gene
41 as a useful target for first line screening, with the RdRp gene suggested as a good target for
42 confirmatory/discriminatory assays [7, 8]. The N gene was central to the USA Centers for Disease
43 Control and Prevention (CDC) in vitro diagnostics emergency protocol, with three different
44 primer/probe sets used against different portions of this viral gene [4]. The CDC protocol also
45 included a probe against human *RPP30*, a single copy gene encoding the protein subunit p30 of the
46 Ribonuclease (RNase) P particle, to ensure the presence of a sufficient number of cells in patient
47 samples and successful isolation of intact nucleic acids.

48 In early versions of these protocols, all probes were labelled with fluorescein amidite (FAM), and
49 separate reactions were therefore needed to detect each target. To increase efficiency, we
50 developed a multiplex assay using 4 different fluorescent labels (FAM, HEX, CAL Fluor Red 610 and
51 Quasar 670) for each of the probes, allowing their detection in a single reaction. In the final version
52 of our assay, we use previously described primers and probes against the well-established SARS-CoV-
53 2 E and N gene targets, as well as two internal controls: human *RPP30* and Phocine Herpes Virus 1
54 (PhHV-1, hereafter referred to as PhHV). The rationale behind the human cellular control is that a
55 considerable number of patients with clinical and radiological signs of COVID-19 are PCR negative;
56 and the poor quality of swab samples with no or little usable patient material is one possible
57 explanation for this [9]. In essence, the *RPP30* control provides a measure of sample quality. In
58 addition, a defined amount of PhHV (resulting in a known Ct value) is spiked into each sample with
59 the lysis buffer at the start of the nucleic acid isolation procedure. Detection of PhHV (using the
60 Glycoprotein B gene as a target) simultaneously controls for extraction and amplification efficiency,
61 as well as ensuring the sample does not contain PCR inhibitors [10, 11].

62 If paired with an in-house RNA extraction protocol, our assay can be performed for less than £2
63 (~2.50 USD) per test, excluding cost of plastics consumables, which could mean a potential 10-fold
64 difference in cost compared to commercial kits. Here we present data that demonstrates equivalent
65 performance to the commercial TaqPath COVID-19 Combo Kit (CE-IVD; Thermo Fisher Scientific) and
66 Abbott RealTime SARS-CoV-2 assay. We also document the utility of inclusion of *RPP30* as a human
67 internal control to provide sample quality information.

68

69 **Results**

70 **N and E gene assays sensitively detect viral RNA**

71 We initially tested qPCR methods for E, RdRp, N1 and N2 in uniplex and duplex assays, the latter in
72 combination with the *RPP30* (HEX) internal control. Whereas we were able to detect as few as 10
73 copies of positive control RNA for E, N1 and N2, and control DNA for *RPP30*, the detection limit for
74 RdRp was only ~100 copies. Nonetheless, each assay was able to correctly identify positive (n=4) and
75 negative (n=1) patient samples (data not shown). We then tested three different 4-plex strategies.
76 All made use of *RPP30* (HEX) and PhHV (Cy5) probes for use as internal controls (controlling for the
77 presence of human cells in patient samples, and successful nucleic acid isolation, respectively), as
78 well as a CFR-labelled (CAL Fluor Red 610) probe for the SARS-CoV-2 E gene. A FAM-labelled probe
79 against a second SARS-CoV-2 target was included in each of the three assays: RdRp, N1 or N2 (N
80 gene). Initial validation tests with these RdRp+E+RPP30+PhHV (RdE-RP), N1+E+RPP30+PhHV (N1E-
81 RP) and N2+E+RPP30+PhHV (N2E-RP) 4-plex assays were performed on cultured virus controls
82 (kindly provided by Rory Gunson, Glasgow, UK). Two independent RNA isolations were performed
83 for the cultured virus, with each used for triplicate RT-qPCR reactions. The resulting Ct values
84 (average \pm SD for the independent isolations) showed that sensitivity of detection was similar for E
85 gene (Ct 21.1 ± 0.55), N1 (22.3 ± 0.04) and N2 (Ct 21.1 ± 0.46), whereas RdRp detection was much

86 less sensitive ($Ct\ 26.9 \pm 0.25$). Very similar results were obtained using the TaqPath COVID-19 assay,
87 which detects N gene, S gene and Orf1ab, with Ct values of 22.2, 22.5 and 21.8 respectively.

88 All three assays were also used to test SARS-CoV-2 positive and negative patient samples ($n=19$), and
89 compared to the TaqPath COVID-19 assay (performed in our laboratory on the ABI 7500 system) and
90 the Abbott RealTime SARS-CoV-2 assay (performed in a different COVID-19 diagnostics centre, using
91 the M2000 system; detects RdRp and N gene). The N1E-RP and N2E-RP assays both correctly
92 identified all 9 samples that had tested positive using the commercial TaqPath and Abbott assays
93 (Table S1). The RdE-RP assay performed less well, identifying 7 of these samples correctly, giving
94 inconclusive results for the other two (P18 and 19): only E gene was detected, but not RdRp. This is
95 consistent with the lower sensitivity of the RdRp assay and the fact that these samples gave the
96 highest Ct values in the other assays. In addition, both N1E-RP and N2E-RP assays identified positive
97 samples that scored negative with the commercial tests, suggesting potentially higher sensitivity of
98 our assays. Of the 10 patient samples that were negative for the Abbott assay, 9 were similarly
99 shown to be negative using the N1E-RP assay, whereas 8 of these were negative for the N2E-RP
100 assay. Patient 12 had previously tested negative using both Abbott and TaqPath assays, and was also
101 negative for N1E-RP; however, this sample tested weakly positive for both COVID-19 targets in the
102 N2E-RP assay. Patient 11, had previously tested negative using the Abbott assay, was inconclusive
103 with TaqPath (1 of 3 COVID-19 targets detected) and also inconclusive with N2E-RP (1 of 2 targets
104 detected), but positive for both targets in the N1E-RP assay. Ct values were high for both P11 and
105 P12, likely indicating low viral load, close to the limit of detection, although we cannot technically
106 exclude the possibility that these were false positives.

107 Our data show that the RdE-RP assay is significantly less sensitive than the N1E-RP and N2E-RP
108 assays, largely due to the relatively low sensitivity of RdRp detection (>20-fold less sensitive),
109 consistent with a recent report [12]. In contrast the N1E-RP and N2E-RP assays were at least as
110 sensitive as two commercial assays, TaqPath COVID-19 Combo Kit (Thermo Fisher Scientific) and

111 Abbott RealTime SARS-CoV-2. For further validation experiments we therefore focussed on the N1E-
112 RP and N2E-RP assays.

113

114 **Multiplex assays for N and E genes can detect between 1 and 50 RNA copies**

115 To determine the detection limit for our N1E-RP and N2E-RP assays, in vitro transcribed RNA
116 controls for each of the SARS-CoV-2 targets were prepared. An equimolar mix was used to make a
117 dilution series (2,000, 200, 20, 10, 2 and 0.2 copies/ μ l) and each of these processed using our nucleic
118 acid isolation protocol. Both extracted and original dilutions were tested in triplicate, enabling us to
119 determine Ct values for 10,000 copies down to 1 copy (10-fold serial dilutions) before and after RNA
120 isolation; a 50 copy control was also included. All probes (E, N1 and N2) reproducibly detected RNA
121 down to 50 copies both pre and post-extraction, although Ct values post-extraction were generally
122 slightly higher (Fig 1A and Table S2). Whereas the N1 probe detected 10 copies reproducibly in both
123 extracted and original dilutions (6 out of 6; 6/6), the N2 probe only detected 10 copies in some
124 reactions (4/6); the E probe detected 10 copies reproducibly in the N2E-RP assay (6/6), but it only
125 picked up 10 copies in half of the N1E-RP reactions (3/6). As would be expected, single copies of RNA
126 were only picked up in a small proportion of reactions for each of the probes: E (2/12), N1 (3/6) and
127 N2 (1/6). The *RPP30* internal control also detected as few as 10 copies of a positive control (Fig S1),
128 showing that signal for this probe represents a good measure of the presence of intact cellular
129 nucleic acids in the patient sample. Our assays therefore have the sensitivity to detect between 1
130 and 50 copies of RNA (Fig 1 and Table S2).

131 To confirm sensitivity using total viral RNA, nucleic acids isolated from cultured SARS-CoV-2 were
132 also used to make a dilution series (10^{-1} to 10^{-6}). Nucleic acids from this dilution series were re-
133 extracted, and dilution series before and after re-extraction were tested in the N1E-RP and N2E-RP
134 assays. Sensitivity of detection for these samples was highest for E gene, followed by N1 and N2 (Fig
135 1C and Table S3). Signal was lost for the 10^{-5} dilution in most cases, consistent with the Ct values of

136 the neat sample (21.3-23.4) and the 100,000-fold reduction in copy number for this dilution
137 (theoretically predicted Ct values, ~38-40). For all extractions and RT-qPCR replicates the signal for
138 the PhHV spike in was highly reproducible, with a Ct value of 32.5 ± 0.40 (mean \pm SD, range 30.7-
139 33.0), indicating robust extraction efficiency and absence of PCR inhibitors.

140

141 **N1E-RP and N2E-RP multiplex assays correctly identify positive patient samples**

142 Next, to confirm reproducibility, the N1E-RP and N2E-RP assays were performed on an additional 89
143 patient samples, with results compared to the TaqPath assay. The patient samples contained both
144 SARS-CoV-2 positives and negatives, and were tested blind. For all samples, the lysis buffer was
145 spiked with MS2 and PhHV controls, internal controls for the TaqPath and N1E-RP/N2E-RP assays
146 respectively. In addition, the same three controls were performed for each assay: an extracted viral
147 transport medium control (negative for SARS-CoV-2 and *RPP30*, positive for PhHV), a non-extracted
148 water only control (negative for all targets) and a non-extracted in vitro transcribed RNA positive
149 control (50 copies; positive for SARS-CoV-2, negative for *RPP30* and PhHV).

150 All positive and negative controls gave the expected results (Table S4). The PhHV control worked for
151 all samples, with consistent Ct values for both the N1E-RP (32.5 ± 1.1) and the N2E-RP assay ($33.3 \pm$
152 1.2 ; Table S4, Fig S2A), confirming reliable and reproducible extraction of nucleic acids from patient
153 samples. Reassuringly, the variability for PhHV in our assays was in the same range as that of the
154 MS2 control used in the TaqPath kit (mean Ct value, 25.6 ± 0.9 ; Table S4, Fig S2A). Out of the 89
155 samples, the TaqPath assay identified 75 samples as negative, 1 as inconclusive and 13 as positive.
156 Both the N1E-RP and N2E-RP assay detected the same 13 positive samples, and the majority of
157 TaqPath negative samples were similarly negative in our assays ($n=74$). For the N1E-RP assay 6 of the
158 negative samples had Ct values between 39.0 and 43.2 for N1 (E gene not detected), suggesting
159 potentially higher sensitivity of the N1 probe in this assay. The sample that was inconclusive for
160 TaqPath (P75) was positive for both N1E-RP and N2E-RP assays, consistent with this being a true

161 positive. In addition, there was one sample (P53) that was negative with TaqPath, but positive for
162 both N1E-RP and N2-ERP, albeit with very high Ct values (between 35.7 and 39.2), close to the limit
163 of detection.

164 In addition to the patient samples (n=108 total), 8 quality control samples from Quality Control for
165 Molecular Diagnostics (QCMD, an external quality assessment organisation) were also tested. All
166 assays (N1E-RP, N2E-RP and TaqPath) gave the same results for the QCMD control samples: 5 tested
167 positive and 3 negative. These results are as expected when compared to the sample identities and
168 data provided by QCMD (Table 1, Fig S3). Altogether, our data establish that the sensitivity of the
169 N1E-RP and N2E-RP assays is similar to that of the TaqPath assay (Fig 2).

170

171 **The human *RPP30* control demonstrates substantial variability with >1,000-fold difference in**
172 **patient material in swabs**

173 In contrast to consistent Ct values for the PhHV internal control, indicating reproducible nucleic acid
174 extraction, the range of Ct values for the human *RPP30* control was much greater, consistent with
175 considerable variability in the amount of usable material present in different patient samples (Table
176 S4, Fig 3 and S1B). Although, the *RPP30* control worked for all samples, Ct values ranged from 20.3
177 to 31.7 for the N1E-RP assay and from 20.3 to 32.1 for the N2E-RP assay. This equates to a difference
178 of between 2,700 and 3,700-fold in extracted nucleic acids between the best and the worst samples.
179 This could mean that compared to a sample of high quality (lowest *RPP30* Ct) with a theoretical
180 SARS-CoV-2 Ct value of 28.6, a sample from the same patient of low quality (highest *RPP30* Ct) would
181 not be picked up as positive, assuming a SARS-CoV-2 detection limit of 40. The absence of a “sample
182 quality” control such as *RPP30* therefore substantially increases the chance of false negative test
183 results when working with suboptimal samples. Complete absence of *RPP30* signal (undetected or Ct
184 >40) clearly indicates that the test result cannot be interpreted and that a repeat test is therefore
185 required. However, utilising *RPP30* Ct values when interpreting an apparent SARS-CoV-2 negative

186 sample requires some consideration: what should the *RPP30* Ct limit be for which to order a repeat
187 test? One option would be to simply set an arbitrary cut-off, e.g. one could decide to re-test any
188 samples with *RPP30* Ct >30, or with Ct values outside the 95% confidence interval. To determine a
189 robust cut-off limit, collection of *RPP30* data for a much larger number of patient samples would be
190 desirable. Nonetheless, *RPP30* data, as it stands, can be useful with the interpretation of cases for
191 which only one of the SARS-CoV-2 targets is (weakly) positive, to prompt potential resampling to
192 obtain a definitive result. False negative test results are an important ongoing issue. Low sample
193 quality, for example in case of self-sampling, is one possible reason for this. Systematic inclusion of
194 an internal human control to provide sample quality metrics, could therefore be an important step
195 to reduce the number of false negatives.

196

197 **Conclusion**

198 Here, we describe a user-friendly protocol for an accurate and affordable SARS-CoV-2 RT-qPCR test.
199 We provide detailed materials and methods to enable others to rapidly set up this assay in their own
200 laboratory or to adapt it to locally available equipment and reagents. Our assays have high analytical
201 sensitivity, equivalent to commercial CE-IVD kits. Ultimately, the clinical sensitivity of any of these
202 diagnostic tests is influenced by multiple factors, including sample timing relative to symptom onset,
203 sample type and sample quality. The inclusion of a human control (*RPP30*) in our assays provides an
204 internal sample quality control that will aid interpretation of test results, and should contribute to
205 reducing false negative results.

206 **Materials and Methods**

207 **Methodological flexibility and improvements**

208 The methods below describe the materials and methods we employed in the development and
209 testing of our assays. There should be some flexibility in terms of the precise reagents and
210 instruments used to perform these multiplex RT-qPCR assays. For example, many companies are
211 able to synthesise high-quality primers and probes with different labels, and alternative Real-Time
212 PCR machines can be used, as long as they are able to detect different channels simultaneously and
213 have been calibrated. A different spike-in to our PhHV control could be used, e.g. lentiviral particles
214 with a GFP transgene and primers/probe targeting GFP would be one option. Also, it is likely that
215 further improvements can be made to our protocol, either generally or to match with local
216 requirements/capabilities. For example, the use of control primers/probe specific to a human RNA
217 transcript (the *RPP30* primers/probe described here detect both RNA and genomic DNA) would give
218 even greater confidence in sample quality, i.e. ensuring that it contains intact RNA. However, it
219 should be stressed that any changes to the protocol may change the sensitivity of SARS-CoV-2
220 detection, and this should be checked using a thorough validation procedure (e.g. as described here)
221 before using these methods for diagnostic purposes.

222

223 **Patient samples**

224 Samples were collected from symptomatic individuals by trained healthcare professionals using
225 combined nose-and-throat swabbing, and processed for diagnostic testing using validated CE-IVD
226 assays. Excess samples were then used to validate the in-house multiplex assays, with specimen
227 anonymization by coding, compliant with Tissue Governance for the South East Scotland Scottish
228 Academic Health Sciences Collaboration Human Annotated BioResource (reference no. SR1452). A

229 variety of swabs and viral transport media (VTM) were used. In each case, swabs were placed in VTM
230 and kept at ambient temperature until processed (within 24 h).

231

232 **Nucleic Acid isolation**

233 For all assays shown in this work, nucleic acids were isolated using the Omega Mag-Bind Viral
234 DNA/RNA 96 Kit (Cat. No. M6246), using the Supplementary Protocol for NP Swabs (April 2020
235 version). Briefly, 200 µl VTM was taken from patient swab sample inside a Class-2 safety cabinet and
236 mixed with 240 µl TNA Lysis Buffer, 1 µl carrier RNA and extraction controls (MS2 and PhHV) in
237 screw capped tubes, for virus inactivation. After incubation at room temperature for at least 15 min,
238 samples were transferred from tubes into 96-well KingFisher Deep well plates (Cat. No. 95040450)
239 containing 280 µl isopropanol and 2 µl Mag-Bind Particles per well, using a Biomek NX^P Automated
240 Liquid Handler (Beckman Coulter). Plates were then moved and the isolation completed on a
241 KingFisher Flex robot (Cat. No. 5400610) as instructed by the manufacturer, including washes with
242 350 µL VHB Buffer and 2x 350 µL SPR Buffer, and RNA finally eluted in 50 µl of nuclease-free water in
243 KingFisher 96 microplates (Cat. No. 97002540). Also see Supplementary Material, Protocol 2.

244 An in-house version of a magnetic bead based isolation was tested and shown to perform similarly in
245 preliminary experiments (data not shown). The use of this protocol could further reduce the cost per
246 test, but would require additional validation. For details of this RNA isolation protocol, see
247 Supplementary Material, Protocol 2.

248

249 **Primers and probes**

250 Primers and probes (Table 2) were synthesised and HPLC purified by LGC BioSearch Technologies
251 (Risskov, Denmark), and dissolved in IDTE (10 mM Tris, 0.1 mM EDTA, pH 8.0) to prepare 100 µM
252 stocks. Pre-prepared primer/probe mixes (FAM-labelled) for N1, N2 and *RPP30* were obtained from

253 Integrated DNA Technologies (IDT, USA; Cat. No. 10006713). Since we developed our assay, N1, N2
254 and *RPP30* primers and probes also became available from IDT as 100 μ M stocks, but can also be
255 purchased from many other reputable oligonucleotide synthesis companies. All nucleic acid stocks
256 and dilutions were prepared in Eppendorf DNA LoBind tubes (Cat. No. 10051232).

257 Primer/probe mixes (50x) were prepared for E gene (20 μ M E_Sarbeco_F1, 20 μ M E_Sarbeco_R2, 10
258 μ M TxRd_E_Sarbeco_P1), RdRp (30 μ M RdRp_SARSr-F2, 40 μ M RdRp_SARSr-R2, 10 μ M
259 FAM_RdRp_SARSr-P2), *RPP30* (25 μ M Hs_RPP30-F, 25 μ M Hs_RPP30-R, 6.25 μ M HEX-Hs_RPP30-P)
260 and PhHV (15 μ M PhHV-F, 15 μ M PhHV-R, 5 μ M Cy5-PhHV-P). The N1 and N2 primers/probes were
261 purchased premixed (\sim 13.3x) from IDT. These individual primer/probe mixes, were then used to
262 prepare a single mix for each of the 4-plex assays: 12.5x for RdE-RP (with equal volumes of each of the
263 relevant mixes), 7.4x for N1E-RP and N2E-RP (with equal volumes of the E, *RPP30* and PhHV mixes,
264 combined with 3.7x volumes of N1 or N2 mix). Mixes were stored at -20°C , with working stocks kept
265 at 4°C .

266

267 **RT-qPCR**

268 All RT-qPCRs were performed on Applied Biosystems 7500 Fast Real-Time PCR Systems and ABI 7500
269 software v2.3, using MicroAmp Fast Optical 0.1mL 96-well reaction plates (Cat. No. 4346906) and
270 Optical Adhesive film (Cat. No. 4311971). For our assays we used the Takara One Step PrimeScript III
271 RT-qPCR kit (Cat. No. RR600B). These were compared to the TaqPath™ COVID-19 Combo Kit (Thermo
272 Fisher Scientific, Cat. No. A47814) and the Abbott RealTime SARS-CoV-2 assay (Cat. No. 09N77-090),
273 used as instructed by the manufacturer. Early tests using mono or duplex RT-qPCR assays were
274 performed using FAM-labelled probes or FAM and HEX-labelled probes respectively (sequences as in
275 Table 2). Ultimately, experiments using the 4-plex assay were performed as described below, with a
276 user-friendly protocol provided in Supplementary Material, Protocol 1.

277 For the 4-plex assays, the same primer/probe sequences and concentrations were used as for the
278 mono/duplex assays. However, different labels and quenchers were used to allow simultaneous
279 detection of four different targets (Table 2). Reaction master mixes were prepared (20 µl per
280 reaction) for each assay, before adding 5 µl of template RNA per reaction, brief centrifugation and
281 starting the PCR program. For the RdE-RP 4-plex assay, per reaction 12.5 µl of One-Step mix, 5.5 µl of
282 nuclease-free water, 2 µl of 12.5x primer/probe mix and 5 µl of template RNA were mixed. For the
283 N1E-RP and N2E-RP 4-plex assays, per reaction 12.5 µl of One-Step mix, 4.16 µl of nuclease-free
284 water, 3.34 µl of 7.4x primer/probe mix and 5 µl of template RNA were mixed. For all 4-plex
285 reactions the PCR program was: 5 min at 52°C, 10 s at 95°C, then 45 cycles of 3 s at 95°C and 30 s at
286 60°C. For detection the FAM, JOE, TEXAS RED and CY5 channels were used.

287

288 **Positive controls**

289 Positive control RNAs generated by in vitro transcription were provided by Sylvie Behillil (Institut
290 Pasteur, Paris, France) for E gene [4] and by Christine Tait-Burkard (Roslin Institute, Edinburgh, UK)
291 for RdRp [7, 8], N1/N3 and N2 [4]. An equimolar mix of all RNAs was prepared at 2.5×10^8 copies/µl,
292 and aliquots stored at -80°C. Dilution series were prepared in nuclease-free water, in Eppendorf DNA
293 LoBind tubes (Cat. No. 10051232), at 2,000, 200, 20, 10, 2 and 0.2 copies/µl.

294

295 **QCMD controls**

296 Quality Control for Molecular Diagnostics (Glasgow, UK) provided controls as part of the “QCMD
297 2020 Coronavirus Outbreak Preparedness (CVOP) EQA Pilot Scheme”. After they were tested blind
298 using our assays, expected results along with sample identities were provided by QCMD.

299

300 **Acknowledgments**

301 We thank Sylvie Behillil (Institut Pasteur, Paris, France), Rory Gunson (NHS Molecular Development
302 in Virology and Microbiology, Glasgow, UK) and QCMD (Glasgow, UK) for reagents; and Angela
303 Ingram, Derek Mills, Maggie Arbuckle, Joyce Begbie, Heather Coupar, Eilidh Guild, Samantha
304 Griffiths, Garry Jempson, Alain Kemp, Frances Rae and Thomas Williams for support. CT-B and MO'S
305 were funded by BBSRC Institute Strategic Programme grant funding (BBS/E/D/20002172,
306 BBS/E/D/20002173). This work was supported by a UK Medical Research Council Human Genetics
307 Unit core grant (MRC, U127580972) and by NHS National Services Scotland, as part of a technology
308 development exercise at the NHS-led University of Edinburgh/NHS Lothian COVID-19 testing centre
309 at the Institute of Genetics and Molecular Medicine.

310

311 **Author contributions**

312 MAMR, APJ, conceived the project. MAMR, LT, JCA, ADi, ADa, KT, JGH, NG, designed experiments.
313 MAMR, LT, JCA, HAB, NG, performed RNA extractions and RT-qPCR experiments. ADa, MCS,
314 performed viral inactivation experiments. FJS-L, CU, MA, ETF, TH, EJJ, FLMC, JKR, MW, CD, DL, CM,
315 SJW, SM, LS, MA, DM, provided technical assistance. MAMR, LT, JCA, HAB, ADa, analysed data.
316 MO'S, MLLM, NW, JS, KT, CT-B, JGH, provided reagents. MAMR, DM, KT, CT-B, JGH, IRA, APJ,
317 supervised the work. IPMT, DM, NW, IJ, IRA, APJ, provided administrative organisation. MAMR
318 produced figures and tables, and wrote the manuscript. All authors had the opportunity to edit the
319 manuscript. All authors approved the final manuscript.

320

321 **Supplementary information**

322 Supplementary material includes 4 figures, 4 tables and 2 protocols.

References

1. Wyllie AL, Fournier J, Casanovas-Massana A, Campbell M, Tokuyama M, Vijayakumar P, et al. Saliva is more sensitive for SARS-CoV-2 detection in COVID-19 patients than nasopharyngeal swabs. 2020:2020.04.16.20067835. doi: 10.1101/2020.04.16.20067835 %J medRxiv.
2. Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A Novel Coronavirus from Patients with Pneumonia in China, 2019. *N Engl J Med*. 2020;382(8):727-33. Epub 2020/01/25. doi: 10.1056/NEJMoa2001017. PubMed PMID: 31978945; PubMed Central PMCID: PMC7092803.
3. Brown JR, O'Sullivan D, Pereira RP, Whale AS, Busby E, Huggett J, et al. Comparison of SARS-CoV2 N gene real-time RT-PCR targets and commercially available mastermixes. 2020:2020.04.17.047118. doi: 10.1101/2020.04.17.047118 %J bioRxiv.
4. WHO in-house assays COVID-19 RT-qPCR. Available from: https://www.who.int/docs/default-source/coronaviruse/whoinhouseassays.pdf?sfvrsn=de3a76aa_2.
5. Pachetti M, Marini B, Benedetti F, Giudici F, Mauro E, Storici P, et al. Emerging SARS-CoV-2 mutation hot spots include a novel RNA-dependent-RNA polymerase variant. *J Transl Med*. 2020;18(1):179. Epub 2020/04/24. doi: 10.1186/s12967-020-02344-6. PubMed PMID: 32321524; PubMed Central PMCID: PMC7174922.
6. Wu A, Peng Y, Huang B, Ding X, Wang X, Niu P, et al. Genome Composition and Divergence of the Novel Coronavirus (2019-nCoV) Originating in China. *Cell Host Microbe*. 2020;27(3):325-8. Epub 2020/02/09. doi: 10.1016/j.chom.2020.02.001. PubMed PMID: 32035028; PubMed Central PMCID: PMC7154514.
7. Corman et al (2020) COVID-19 RT-qPCR protocol v2 Available from: <https://www.who.int/docs/default-source/coronaviruse/protocol-v2-1.pdf>.
8. Corman VM, Landt O, Kaiser M, Molenkamp R, Meijer A, Chu DK, et al. Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. *Euro Surveill*. 2020;25(3). Epub 2020/01/30. doi: 10.2807/1560-7917.ES.2020.25.3.2000045. PubMed PMID: 31992387; PubMed Central PMCID: PMC7698269.
9. Ai T, Yang Z, Hou H, Zhan C, Chen C, Lv W, et al. Correlation of Chest CT and RT-PCR Testing in Coronavirus Disease 2019 (COVID-19) in China: A Report of 1014 Cases. *Radiology*. 2020:200642. Epub 2020/02/27. doi: 10.1148/radiol.20200642. PubMed PMID: 32101510; PubMed Central PMCID: PMC7233399.
10. Niesters HG. Quantitation of viral load using real-time amplification techniques. *Methods*. 2001;25(4):419-29. Epub 2002/02/16. doi: 10.1006/meth.2001.1264. PubMed PMID: 11846611.
11. Stranska R, Schuurman R, de Vos M, van Loon AM. Routine use of a highly automated and internally controlled real-time PCR assay for the diagnosis of herpes simplex and varicella-zoster virus infections. *J Clin Virol*. 2004;30(1):39-44. Epub 2004/04/10. doi: 10.1016/j.jcv.2003.08.006. PubMed PMID: 15072752.
12. Vogels CBF, Brito AF, Wyllie AL, Fauver JR, Ott IM, Kalinich CC, et al. Analytical sensitivity and efficiency comparisons of SARS-CoV-2 RT-qPCR primer-probe sets. *Nat Microbiol*. 2020. Epub 2020/07/12. doi: 10.1038/s41564-020-0761-6. PubMed PMID: 32651556.

Table 1: N1E-RP, N2E-RP and TaqPath assays all correctly identify COVID-19/SARS-CoV-2 positive QCMD quality control samples

QCMD Sample	Content	Log10 dPCR Copies/ml	N1E-RP assay			N2E-RP assay			TaqPath assay			Conclusion		
			N1	E	PhHV	N2	E	PhHV	N	ORF1ab	S	N1E-RP	N2E-RP	Taq Path
CVOP20S2-01	SARS-CoV-2	4.30	29.72	28.98	32.22	29.58	29.14	32.98	28.06	28.21	28.15	P	P	P
CVOP20S2-02	Coronavirus – NL63	4.64	UD	UD	33.54	UD	UD	32.79	UD	UD	UD	N	N	N
CVOP20S2-03	SARS-CoV-2	3.30	32.26	31.62	32.66	32.70	31.8	32.52	30.24	29.22	30.02	P	P	P
CVOP20S2-04	Coronavirus – OC43	4.03	UD	UD	32.64	UD	UD	33.01	UD	UD	UD	N	N	N
CVOP20S2-05	Transport medium	-	UD	UD	32.54	UD	UD	32.45	UD	UD	UD	N	N	N
CVOP20S2-06	SARS-CoV-2	4.30	29.77	28.94	32.90	29.56	28.82	32.67	27.96	27.79	27.63	P	P	P
CVOP20S2-07	SARS-CoV-2	5.30	26.18	25.42	31.64	26.20	25.44	31.93	24.63	24.52	24.65	P	P	P
CVOP20S2-08	SARS-CoV-2	2.30	35.69	34.55	33.02	35.66	35.88	32.74	35.89	36.62	36.14	P	P	P

UD, undetermined; P, positive; N, negative

Table 2. Primer/Probe details for 4-plex assays

Oligonucleotide ID	Sequence (5'-3')	Target	Concentration (nM)	Reference
E_Sarbeco_F1	ACAGGTACGTTAATAGTTAATAGCGT	SARS-CoV-2 E gene	400	[7, 8]
E_Sarbeco_R2	ATATTGCAGCAGTACGCACACA	SARS-CoV-2 E gene	400	[7, 8]
TxRd_E_Sarbeco_P1*	CFR-610-ACACTAGCCATCCTTACTGCGCTTCG-BHQ2	SARS-CoV-2 E gene	200	[7, 8]
RdRp_SARsR-F2	GTGARATGGTCATGTGTGGCGG	SARS-CoV-2 RdRp	600	[7, 8]
RdRp-SARsR-R1	CARATGTTAAASACACTATTAGCATA	SARS-CoV-2 RdRp	800	[7, 8]
FAM_RdRp_SARsR-P2	FAM-CAGGTGGAACCTCATCAGGAGATGC-BHQ1	SARS-CoV-2 RdRp	200	[7, 8]
2019-nCoV_N1-F	GACCCCAAATCAGCGAAAT	SARS-CoV-2 N gene	500	[4]
2019-nCoV_N1-R	TCTGGTACTGCCAGTTGAATCTG	SARS-CoV-2 N gene	500	[4]
2019-nCoV_N1-P	FAM-ACCCCGCATTACGTTTGGTGGACC-BHQ1	SARS-CoV-2 N gene	125	[4]
2019-nCoV_N2-F	TTACAAACATTGGCCGCAAA	SARS-CoV-2 N gene	500	[4]
2019-nCoV_N2-R	GCGCGACATTCCGAAGAA	SARS-CoV-2 N gene	500	[4]
2019-nCoV_N2-P	FAM-ACAATTTGCCCCAGCGCTTCAG-BHQ1	SARS-CoV-2 N gene	125	[4]
Hs_RPP30-F	AGATTTGGACCTGCGAGCG	Human <i>RPP30</i>	500	[4]
Hs_RPP30-R	GAGCGGCTGTCTCCACAAGT	Human <i>RPP30</i>	500	[4]
HEX-Hs_RPP30-P	HEX-TTCTGACCTGAAGGCTCTGCGCG-BHQ1	Human <i>RPP30</i>	125	[4]
PhHV-F	GGGCGAATCACAGATTGAATC	PhHV-1 Glycoprotein B	300	[11]
PhHV-R	GCGGTTCCAAACGTACCA	PhHV-1 Glycoprotein B	300	[11]
Cy5-PhHV-P**	Quasar-670- TTTTTATGTGTCCGCCACCATCTGGATC-BHQ2	PhHV-1 Glycoprotein B	100	[11]

* Probe named TxRd for simplicity, CAL Flour Red (CFR-610) has virtually identical properties to TexRed

** Probe named Cy5 for simplicity. Quasar 670 has virtually identical properties to Cy5




Figure 1. The N1E-RP and N2E-RP 4-plex assays detect low levels of SARS-CoV-2 RNA.

A, B: 1 to 10,000 copies of SARS-CoV-2 control RNA (IVT, in vitro transcribed) were used for N1E-RP and N2E-RP RT-qPCR assays before and after nucleic acid extraction.

C: RNA was isolated from cultured SARS-CoV-2, a serial dilution prepared, and re-extracted.

N1E-RP and N2E-RP assays were performed before and after re-extraction. Mean \pm SD for technical triplicates shown for each (A-C), along with trend line equations and R^2 values (B,C).

Also, see Table S2 and S3.




Figure 2. The N1E-RP and N2E-RP 4-plex assays perform similarly to the TaqPath assay, correctly identifying positive and negative patient samples.

A: The TaqPath, N1E-RP and N2E-RP assays each identified a similar numbers of positives and negatives among 108 patient samples. Inconclusive: only one of the SARS-CoV-2 targets was detected.

B, C: Ct values for each of the SARS-CoV-2 targets in the TaqPath (N, Orf1ab, S), N1E-RP (N1, E) and N2E-RP (N2, E) are very similar (for n=24-26 positive patients). In B, mean \pm SEM of individual patient data points. Also, see Table S1 and S4.




Figure 3. The *RPP30* control indicates substantial variability in sample quantity/quality, impacting on assay sensitivity.

A, B: *RPP30* Ct values for 108 patient samples ranked from low to high (based on N1E-RP ranks) for N1E-RP and N2E-RP assays. SARS-CoV-2 positives marked in red.

C, D: Comparison of actual (Act) and *RPP30*-normalised (Norm) Ct values for SARS-CoV-2 targets (normalised: Δ Ct compared to lowest *RPP30* Ct subtracted from SARS-CoV-2 Ct value)

Supplementary material to:

A sensitive and affordable multiplex RT-qPCR assay for SARS-CoV-2 detection

Martin A.M. Reijns^{1,*}, Louise Thompson², Juan Carlos Acosta³, Holly A. Black^{2,4}, Francisco J. Sanchez-Luque^{1,5}, Austin Diamond², Alison Daniels⁶, Marie O'Shea⁷, Carolina Ugenti⁴, Maria C. Sanchez⁶, Michelle L.L. McNab⁶, Martyna Adamowicz⁴, Elias T. Friman¹, Toby Hurd¹, Edward J. Jarman¹, Frederic Li Mow Chee³, Jacqueline K. Rainger¹, Marion Walker³, Camilla Drake¹, Dasa Longman¹, Christine Mordstein^{1,8}, Sophie J. Warlow⁴, Stewart McKay¹, Louise Slater², Morad Ansari², Ian P.M. Tomlinson³, David Moore², Nadine Wilkinson⁹, Jill Shepherd⁹, Kate Templeton⁹, Ingolfur Johannessen⁹, Christine Tait-Burkard⁷, Jürgen G. Haas⁶, Nick Gilbert¹, Ian R. Adams¹, Andrew P. Jackson¹

1. MRC Human Genetics Unit, Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, UK

2. NHS Lothian, The South East of Scotland Clinical Genetic Service, Western General Hospital, Edinburgh, UK

3. Cancer Research UK Edinburgh Centre, Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, UK

4. Centre for Genomic & Experimental Medicine, Institute of Genetics and Molecular Medicine, University of Edinburgh, Edinburgh, UK

5. Centre Pfizer-University of Granada-Andalusian Government for Genomics and Oncological Research (Genyo), Granada, Spain

6. Division of Infection Medicine, Edinburgh Medical School, University of Edinburgh, Edinburgh, UK

7. The Roslin Institute and Royal (Dick) School of Veterinary Studies, University of Edinburgh, Edinburgh, UK

8. The Milner Centre for Evolution, Department of Biology and Biochemistry, University of Bath, Bath, UK

9. NHS Lothian, Medical Microbiology and Virology Service, Royal Infirmary of Edinburgh, Edinburgh UK

* Correspondence to MAMR, martin.reijns@igmm.ed.ac.uk

Supplementary material: 4 figures, 4 tables and 2 protocols




Figure S1. The human *RPP30* control probe detects as few as 10 copies of control DNA.

A: Ct values for *RPP30* on a serial dilution of positive control plasmid DNA (100,000 down to 10 copies were tested)

B: Ct values for *RPP30* on nucleic acids (NA) isolated from human cultured cells (1 = undiluted) and NA isolated from a serial dilution of the same cell suspension. Negative control samples did not show any amplification. Data points and error bars, mean \pm SD (n=2 technical replicates). R^2 values given for trend line fitting.




Figure S2. High reproducibility for extraction controls, but high variability for the human *RPP30* control.

A, B: Ct values for internal controls, MS2 for TaqPath and PhHV for N1E-RP and N2E-RP assays (A), and *RPP30* controls (B)

C: Ct values for PhHV and *RPP30* controls for N1E-RP and N2E-RP assays, ranked by *RPP30* values from the N1E-RP assay, confirm that variability does not substantially correlate with extraction efficiency




Figure S3. N1E-RP and N2E-RP assay results for QCMD controls

A, B: Ct values for N1 and E targets (**A**) and N2 and E targets (**B**) were obtained for QCMD control samples. These controls were provided as part of the QCMD 2020 Coronavirus Outbreak Preparedness (CVOP) EQA Pilot Scheme, and contain different amounts of SARS-CoV-2 virus. Log10 dPCR values were obtained by QCMD using a digital droplet PCR assay (modified from [7, 8]). Also, see Table 1.

Table S1: The multiplex assay detecting RdRp and E gene (RdE-RP) is not sufficiently sensitive; assays detecting N and E gene (N1E-RP, N2E-RP) are

Patient	RdE-RP		N1E-RP		N2E-RP		All assays	TaqPath assay			Abbott	Conclusion				
	E	RdRp	E	N1	E	N2	RPP30	N	S	Orf1ab	Ct*	RdE-RP	N1E-RP	N2E-RP	Taq Path	Abbott
P1	UD	UD	UD	UD	UD	UD	28.2 ± 0.56	UD	UD	UD	UD	N	N	N	N	N
P2	UD	UD	UD	UD	UD	UD	31.8 ± 0.58	UD	UD	UD	UD	N	N	N	N	N
P3	UD	UD	UD	UD	UD	UD	29.3 ± 0.54	UD	UD	UD	UD	N	N	N	N	N
P4	UD	UD	UD	UD	UD	UD	27.8 ± 0.51	UD	UD	UD	UD	N	N	N	N	N
P5	18.72	24.17	18.19	19.33	17.50	18.16	22.7 ± 1.37	20.09	20.73	20.03	18.26	P	P	P	P	P
P6	20.58	25.39	19.90	21.55	20.27	20.28	24.9 ± 1.65	22.80	22.78	22.04	21.39	P	P	P	P	P
P7	24.23	28.65	23.41	25.09	22.85	23.97	27.1 ± 0.79	25.94	26.27	25.64	23.70	P	P	P	P	P
P8	25.74	32.33	25.26	26.09	24.56	24.92	27.6 ± 0.49	27.00	27.90	27.19	25.78	P	P	P	P	P
P9	UD	UD	UD	UD	UD	UD	28.2 ± 0.29	UD	UD	UD	UD	N	N	N	N	N
P10	UD	UD	UD	UD	UD	UD	27.9 ± 0.48	UD	UD	UD	UD	N	N	N	N	N
P11	UD	UD	35.33	37.98	33.95	UD	30.6 ± 0.49	UD	UD	39.42	UD	N	P	Inc	Inc	N
P12	UD	UD	UD	UD	34.81	38.03	27.5 ± 0.33	UD	UD	UD	UD	N	N	P	N	N
P13	20.26	24.85	19.54	20.76	18.94	19.73	24.1 ± 1.64	21.35	22.41	21.85	19.84	P	P	P	P	P
P14	UD	UD	UD	UD	UD	UD	27.9 ± 0.49	UD	UD	UD	UD	N	N	N	N	N
P15	25.50	31.64	24.94	27.06	24.37	25.43	25.9 ± 0.38	27.50	27.30	26.73	25.27	P	P	P	P	P
P16	UD	UD	UD	UD	UD	UD	27.9 ± 0.36	UD	UD	UD	UD	N	N	N	N	N
P17	17.44	26.97	17.23	16.08	16.85	16.93	21.9 ± 1.67	16.06	18.46	17.02	14.16	P	P	P	P	P
P18	29.77	UD	29.17	31.10	29.20	30.28	29.7 ± 0.43	31.54	31.30	30.71	30.32	Inc	P	P	P	P
P19	31.76	UD	31.13	34.03	30.21	32.40	27.4 ± 0.63	33.87	35.22	33.71	32.49	Inc	P	P	P	P

* The output for the Abbott test is given in a single CN value, which is approximately equivalent to Ct minus 10 (so Ct = CN+10)

UD, undetermined; P, positive; N, negative; Inc, inconclusive

Supplement: An affordable multiplex RT-qPCR assay for SARS-CoV-2 detection July 14, 2020

Table S2: N1E-RP and N2E-RP assay Ct values for SARS-CoV-2 RNA controls (1 to 10,000 copies) pre- and post-extraction (values used for Fig 1A and B)

# copies	10,000	1,000	100	50	10	1
N1, N1E-RP assay pre-extraction						
Rep 1	22.83	26.49	30.30	31.42	33.49	35.87
Rep 2	23.36	26.62	30.50	31.05	34.43	Undetermined
Rep 3	23.30	26.77	29.32	32.38	34.94	Undetermined
Mean	23.17	26.62	30.04	31.62	34.29	35.87
E gene, N1E-RP pre-extraction						
Rep 1	24.26	27.98	31.37	33.60	36.26	Undetermined
Rep 2	24.74	27.73	32.73	35.22	Undetermined	Undetermined
Rep 3	24.43	27.90	31.34	32.36	Undetermined	Undetermined
Mean	24.48	27.87	31.81	33.73	36.26	Undetermined
N2, N2E-RP assay pre-extraction						
Rep 1	26.63	30.49	33.99	34.63	37.34	38.72
Rep 2	26.88	29.99	34.01	35.06	Undetermined	Undetermined
Rep 3	26.70	30.58	33.79	37.34	36.99	Undetermined
Mean	26.74	30.35	33.93	34.47	37.16	38.72
E gene, N2E-RP assay pre-extraction						
Rep 1	25.50	28.71	32.84	33.37	35.25	Undetermined
Rep 2	25.70	28.71	33.05	33.24	35.93	36.64
Rep 3	25.50	29.56	32.29	33.85	35.05	Undetermined
Mean	25.57	28.99	32.73	33.49	35.41	36.64
N1, N1E-RP assay post-extraction						
Rep 1	25.64	29.02	33.14	33.59	35.09	Undetermined
Rep 2	25.14	28.80	33.41	33.58	35.37	36.14
Rep 3	25.50	29.01	33.22	33.87	37.62	37.04
Mean	25.43	28.94	33.25	33.68	36.03	36.59
E gene, N1E-RP assay post-extraction						
Rep 1	25.99	29.24	33.26	35.01	35.59	Undetermined
Rep 2	25.39	28.88	34.04	33.87	33.64	Undetermined
Rep 3	25.61	29.22	32.47	33.81	Undetermined	Undetermined
Mean	25.66	29.11	33.26	34.23	34.61	Undetermined
N2, N2E-RP assay post-extraction						
Rep 1	28.69	32.39	36.86	36.01	38.35	Undetermined
Rep 2	28.33	31.69	35.75	35.57	38.17	Undetermined
Rep 3	28.79	32.56	35.40	36.21	Undetermined	Undetermined
Mean	28.60	32.21	36.01	35.93	38.26	Undetermined
E gene, N2E-RP assay post-extraction						
Rep 1	26.72	29.89	33.85	33.40	Undetermined	Undetermined
Rep 2	26.45	30.01	33.38	34.53	35.87	Undetermined
Rep 3	26.96	30.30	33.79	34.56	36.10	36.40
Mean	26.71	30.07	33.67	34.16	35.98	36.40

Supplement: An affordable multiplex RT-qPCR assay for SARS-CoV-2 detection July 14, 2020

Table S3: N1E-RP and N2E-RP assay Ct values for cultured SARS-CoV-2 dilution series (before and after re-extraction; values used for Fig 1C)

	neat	10 ⁻¹	10 ⁻²	10 ⁻³	10 ⁻⁴	10 ⁻⁵	10 ⁻⁶
N1, N1E-RP assay							
1	22.53	26.46	29.42	32.21	37.19	UD	UD
2	22.83	26.03	29.87	32.79	UD	UD	UD
3	22.40	25.96	29.35	33.48	37.16	UD	UD
Mean	22.59	26.15	29.55	32.83	37.18	UD	UD
E gene, N1E-RP assay							
1	21.31	24.77	27.97	31.35	34.22	UD	UD
2	21.38	24.38	28.03	31.50	35.27	UD	UD
3	21.35	24.41	27.84	31.55	35.63	UD	UD
Mean	21.35	24.52	27.94	31.46	35.04	UD	UD
N2, N2E-RP assay							
1	23.08	26.76	29.95	33.56	37.21	38.06	UD
2	23.36	26.64	29.79	34.81	36.50	38.29	UD
3	23.32	26.46	30.14	33.49	36.44	UD	UD
Mean	23.25	26.62	29.96	33.95	36.72	38.17	UD
E gene, N2E-RP assay							
1	22.00	25.48	28.78	32.41	36.34	UD	UD
2	22.22	25.42	28.57	32.59	UD	40.63	UD
3	22.15	25.31	28.87	32.31	39.68	UD	UD
Mean	22.12	25.40	28.74	32.44	38.01	40.63	UD
	0.5	10 ⁻¹	10 ⁻²	10 ⁻³	10 ⁻⁴	10 ⁻⁵	10 ⁻⁶
N1, N1E-RP assay after re-extraction							
1	24.95	27.48	30.79	34.27	UD	UD	UD
2	24.93	27.54	31.08	34.77	37.44	UD	UD
3	25.04	27.12	30.69	34.26	UD	UD	UD
Mean	24.97	27.38	30.85	34.44	37.44	UD	UD
E gene, N1E-RP assay after re-extraction							
1	23.85	26.56	29.63	33.49	UD	UD	UD
2	23.86	26.53	29.85	33.30	UD	UD	UD
3	24.18	26.59	29.59	32.77	35.54	UD	UD
Mean	23.96	26.56	29.69	33.19	35.54	UD	UD
N2, N2E-RP assay after re-extraction							
1	25.90	28.27	31.84	35.46	37.68	UD	UD
2	25.76	28.36	31.78	34.97	UD	UD	UD
3	25.53	28.27	31.13	34.36	UD	UD	UD
Mean	25.73	28.30	31.58	34.93	37.68	UD	UD
E gene, N2E-RP assay after re-extraction							
1	24.86	27.37	30.73	33.22	UD	UD	UD
2	25.00	27.55	30.81	34.54	UD	UD	UD
3	23.65	27.62	31.25	34.19	35.96	UD	UD
Mean	24.51	27.51	30.93	33.99	35.96	UD	UD

Table S4: The N1E-RP and N2E-RP COVID-19 4-plex assays perform as well as the TaqPath CE-IVD assay

Patient	N1E-RP assay				N2E-RP assay				TaqPath assay				Conclusion		
	N1	E	RPP30	PhHV	N2	E	RPP30	PhHV	N	ORF1a b	S	MS2	N1E-RP	N2E-RP	TaqPath
P20	UD	UD	25.56	30.74	UD	UD	25.25	31.41	UD	UD	UD	24.31	N	N	N
P21	UD	UD	29.53	34.27	UD	UD	29.76	34.64	UD	UD	UD	26.50	N	N	N
P22	UD	UD	24.59	33.10	UD	UD	24.47	34.14	UD	UD	UD	25.01	N	N	N
P23	UD	UD	30.71	33.47	UD	UD	30.53	33.93	UD	UD	UD	25.90	N	N	N
P24	UD	UD	30.67	33.89	UD	UD	30.57	34.87	UD	UD	UD	26.04	N	N	N
P25	UD	UD	26.81	32.22	UD	UD	26.86	32.71	UD	UD	UD	24.34	N	N	N
P26	UD	UD	26.52	32.60	UD	UD	26.60	33.39	UD	UD	UD	24.22	N	N	N
P27	UD	UD	24.72	32.38	UD	UD	24.83	33.63	UD	UD	UD	25.62	N	N	N
P28	UD	UD	29.83	34.63	UD	UD	29.98	37.73	UD	UD	UD	25.68	N	N	N
P29	UD	UD	25.23	32.30	UD	UD	25.55	32.94	UD	UD	UD	24.59	N	N	N
P30	39.97	UD	26.45	32.73	UD	UD	26.92	33.71	UD	UD	UD	25.62	N	N	N
P31	UD	UD	29.77	33.12	UD	UD	30.10	33.58	UD	UD	UD	25.23	N	N	N
P32	UD	UD	26.34	32.17	UD	UD	26.36	32.39	UD	UD	UD	24.51	N	N	N
P33	UD	UD	24.60	32.81	UD	UD	24.63	33.31	UD	UD	UD	25.25	N	N	N
P34	UD	UD	31.59	34.52	UD	UD	31.11	34.22	UD	UD	UD	25.43	N	N	N
P35	UD	UD	23.00	33.15	UD	UD	22.77	33.35	UD	UD	UD	25.97	N	N	N
P36	UD	UD	25.61	30.87	UD	UD	26.31	32.66	UD	UD	UD	24.95	N	N	N
P37	UD	UD	29.57	34.96	UD	UD	29.28	35.14	UD	UD	UD	25.78	N	N	N
P38	UD	UD	31.26	34.22	UD	UD	31.14	34.67	UD	UD	UD	26.81	N	N	N
P39	UD	UD	21.62	31.94	UD	UD	21.50	32.33	UD	UD	UD	24.79	N	N	N
P40	UD	UD	30.16	33.34	UD	UD	29.42	33.91	UD	UD	UD	25.82	N	N	N
P41	UD	UD	22.61	32.60	UD	UD	22.49	33.39	UD	UD	UD	25.45	N	N	N
P42	UD	UD	21.32	31.32	UD	UD	21.16	32.45	UD	UD	UD	25.23	N	N	N
P43	UD	UD	27.02	32.57	UD	UD	26.31	32.17	UD	UD	UD	25.01	N	N	N

Patient	N1E-RP assay				N2E-RP assay				TaqPath assay				Conclusion		
	N1	E	RPP30	PhHV	N2	E	RPP30	PhHV	N	ORF1a b	S	MS2	N1E-RP	N2E-RP	TaqPath
P44	34.26	31.95	24.16	31.99	33.42	32.56	23.96	32.50	32.77	34.76	33.12	25.17	P	P	P
P45	39.35	UD	30.63	33.82	UD	UD	30.75	35.61	UD	UD	UD	27.19	N	N	N
P46	UD	UD	21.65	31.33	UD	UD	21.68	32.11	UD	UD	UD	24.49	N	N	N
P47	UD	UD	24.73	33.07	UD	UD	24.46	33.90	UD	UD	UD	25.31	N	N	N
P48	UD	UD	24.83	32.74	UD	UD	24.55	33.01	UD	UD	UD	25.82	N	N	N
P49	UD	UD	29.62	33.85	UD	UD	29.32	34.36	UD	UD	UD	26.10	N	N	N
P50	UD	UD	24.81	32.67	UD	UD	24.68	33.23	UD	UD	UD	26.37	N	N	N
P51	UD	UD	30.65	34.44	UD	UD	30.64	37.60	UD	UD	UD	26.99	N	N	N
P52	25.95	24.70	27.20	31.59	25.63	25.35	26.66	32.75	24.55	25.08	25.14	25.97	P	P	P
P53	36.96	37.19	25.79	31.76	36.93	37.77	25.43	32.55	UD	UD	UD	25.63	P	P	N
P54	UD	UD	25.89	32.51	UD	UD	25.75	33.36	UD	UD	UD	25.25	N	N	N
P55	UD	UD	23.41	31.87	UD	UD	23.54	32.70	UD	UD	UD	25.31	N	N	N
P56	UD	UD	28.33	32.86	UD	UD	28.41	33.26	UD	UD	UD	25.66	N	N	N
P57	UD	UD	28.34	32.90	UD	UD	28.40	33.24	UD	UD	UD	26.14	N	N	N
P58	33.38	32.39	30.65	33.38	34.07	33.65	30.10	34.12	33.29	37.49	34.89	26.82	P	P	P
P59	39.03	UD	28.94	32.99	UD	UD	28.64	33.57	UD	UD	UD	25.77	N	N	N
P60	39.53	UD	27.94	31.77	UD	UD	27.67	32.46	UD	UD	UD	25.11	N	N	N
P61	UD	UD	26.81	31.93	UD	UD	26.65	32.29	UD	UD	UD	24.90	N	N	N
P62	UD	UD	32.13	36.32	UD	UD	31.71	36.92	UD	UD	UD	27.27	N	N	N
P63	UD	UD	28.42	32.91	UD	UD	27.90	33.90	UD	UD	UD	25.95	N	N	N
P64	UD	UD	31.67	34.94	UD	UD	31.54	35.91	UD	UD	UD	27.53	N	N	N
P65	UD	UD	22.81	32.49	UD	UD	22.49	33.30	UD	UD	UD	25.98	N	N	N
P66	29.86	29.45	22.54	31.03	30.72	30.51	22.53	31.77	29.45	30.68	30.76	24.86	P	P	P
P67	32.66	31.37	24.95	31.89	32.65	32.39	25.25	32.77	32.25	34.90	33.81	25.78	P	P	P
P68	UD	UD	24.51	32.57	UD	UD	24.28	33.37	UD	UD	UD	25.67	N	N	N
P69	UD	UD	26.49	33.05	UD	UD	26.57	34.02	UD	UD	UD	25.48	N	N	N

Patient	N1E-RP assay				N2E-RP assay				TaqPath assay				Conclusion		
	N1	E	RPP30	PhHV	N2	E	RPP30	PhHV	N	ORF1a b	S	MS2	N1E-RP	N2E-RP	TaqPath
P70	UD	UD	24.67	31.73	UD	UD	24.43	32.22	UD	UD	UD	24.40	N	N	N
P71	40.23	UD	20.35	30.96	UD	UD	20.32	31.66	UD	UD	UD	24.65	N	N	N
P72	43.15	UD	22.83	32.07	UD	UD	22.59	32.43	UD	UD	UD	25.15	N	N	N
P73	UD	UD	28.21	33.01	UD	UD	28.13	33.57	UD	UD	UD	25.95	N	N	N
P74	UD	UD	25.78	32.16	UD	UD	25.66	32.53	UD	UD	UD	24.71	N	N	N
P75	38.44	35.68	26.65	32.44	39.20	38.93	26.31	33.25	35.47	UD	UD	25.79	P	P	Inc
P76	22.69	22.62	25.77	32.01	23.04	23.42	25.12	32.39	21.91	22.55	22.77	26.69	P	P	P
P77	21.47	21.60	23.90	33.21	21.84	22.33	23.98	32.68	21.16	22.53	22.38	30.08	P	P	P
P78	UD	UD	24.49	32.73	UD	UD	24.37	33.07	UD	UD	UD	25.72	N	N	N
P79	UD	UD	27.14	33.85	UD	UD	27.06	35.00	UD	UD	UD	26.04	N	N	N
P80	UD	UD	22.78	32.70	UD	UD	22.89	33.24	UD	UD	UD	25.80	N	N	N
P81	UD	UD	23.01	32.61	UD	UD	22.74	32.79	UD	UD	UD	25.57	N	N	N
P82	UD	UD	26.99	31.79	UD	UD	26.84	32.72	UD	UD	UD	25.52	N	N	N
P83	UD	UD	31.29	35.55	UD	UD	31.42	35.57	UD	UD	UD	27.24	N	N	N
P84	UD	UD	22.18	31.85	UD	UD	21.99	32.82	UD	UD	UD	24.75	N	N	N
P85	UD	UD	24.37	32.50	UD	UD	24.14	33.25	UD	UD	UD	25.85	N	N	N
P86	UD	UD	23.23	31.79	UD	UD	23.15	32.62	UD	UD	UD	24.80	N	N	N
P87	UD	UD	23.10	31.79	44.55	UD	22.99	31.89	UD	UD	UD	24.76	N	N	N
P88	UD	UD	24.51	32.62	UD	UD	24.48	33.49	UD	UD	UD	25.17	N	N	N
P89	UD	UD	24.67	32.02	UD	UD	24.45	34.68	UD	UD	UD	25.17	N	N	N
P90	25.58	25.96	23.32	31.65	26.04	26.56	23.27	32.18	24.15	24.71	24.87	24.73	P	P	P
P91	UD	UD	20.27	31.55	UD	UD	20.30	31.207	UD	UD	UD	24.95	N	N	N
P92	17.51	16.25	20.36	29.33	17.24	16.79	20.49	31.68	17.28	16.97	17.10	27.18	P	P	P
P93	UD	UD	22.97	32.74	UD	UD	22.89	33.44	UD	UD	UD	25.60	N	N	N
P94	UD	UD	23.60	32.46	UD	UD	23.70	33.29	UD	UD	UD	25.16	N	N	N
P95	UD	UD	25.18	32.93	UD	UD	24.99	33.28	UD	UD	UD	26.64	N	N	N

Patient	N1E-RP assay				N2E-RP assay				TaqPath assay				Conclusion		
	N1	E	RPP30	PhHV	N2	E	RPP30	PhHV	N	ORF1a b	S	MS2	N1E-RP	N2E-RP	TaqPath
P96	UD	UD	23.53	33.50	UD	UD	23.31	34.08	UD	UD	UD	25.88	N	N	N
P97	UD	UD	25.64	31.92	UD	UD	25.09	31.82	UD	UD	UD	24.83	N	N	N
P98	21.50	20.39	23.62	31.84	21.29	20.90	23.20	32.92	20.73	20.43	21.33	25.97	P	P	P
P99	UD	UD	23.01	32.16	UD	UD	23.43	34.11	UD	UD	UD	27.60	N	N	N
P100	18.24	18.92	21.51	32.04	18.68	19.44	21.99	32.50	17.91	18.05	18.69	25.49	P	P	P
P101	UD	UD	23.77	32.02	UD	UD	24.05	32.62	UD	UD	UD	25.25	N	N	N
P102	UD	UD	24.71	30.80	UD	UD	24.59	31.29	UD	UD	UD	24.31	N	N	N
P103	UD	UD	23.61	32.64	UD	UD	23.55	32.82	UD	UD	UD	25.13	N	N	N
P104	UD	UD	23.12	31.92	UD	UD	22.77	32.44	UD	UD	UD	24.57	N	N	N
P105	24.75	25.23	25.61	31.03	25.26	25.85	25.33	31.82	25.95	26.11	26.42	24.74	P	P	P
P106	UD	UD	26.67	32.93	UD	UD	26.60	32.68	UD	UD	UD	25.36	N	N	N
P107	33.90	32.43	21.76	31.97	34.09	33.04	21.71	31.89	32.29	33.97	32.74	24.80	P	P	P
P108	UD	UD	27.70	32.01	UD	UD	27.35	33.17	UD	UD	UD	24.69	N	N	N
-ve (extr)	UD	UD	UD	31.75	UD	UD	UD	32.77	UD	UD	UD	25.18	OK	OK	OK
-ve	UD	UD	UD	UD	UD	UD	UD	UD	UD	UD	UD	UD	OK	OK	OK
+ve	30.89	34.15	*	UD	30.35	34.49	*	UD	31.28	31.88	31.23	UD	OK	OK	OK

* FAM-positive samples give ~5% signal bleed through into the JOE channel; this should be taken into account for samples without any true RPP30 (HEX) signal
 UD, undetermined; P, positive; N, negative; Inc, inconclusive

Supplementary Protocol 1: 4-plex SARS-CoV-2 RT-qPCR assay

Primers/probes

Dissolve primers and probes (Table P1; HPLC purified) in 10 mM Tris, 0.1 mM EDTA, pH 8.0 (IDTE Cat. No. 11-05-01-09, or similar) for 100 μ M stocks. Prepare primer/probe mixes (Tables P2-P7), and store aliquots at -20°C. Working stocks can be stored at 4°C.

Table P1. Primer/Probe details for 4-plex assays

Oligonucleotide ID	Sequence (5'-3')	Target	Reference
E_Sarbeco_F1	ACAGGTACGTTAATAGTTAATAGCGT	SARS-CoV-2, E gene	[1, 2]
E_Sarbeco_R2	ATATTGCAGCAGTACGCACACA	SARS-CoV-2, E gene	[1, 2]
TxRd_E_Sarbeco_P1*	CFR-610-ACACTAGCCATCCTTACTGCGCTTCG-BHQ2	SARS-CoV-2, E gene	[1, 2]
2019-nCoV_N1-F	GACCCCAAAATCAGCGAAAT	SARS-CoV-2, N gene	[3]
2019-nCoV_N1-R	TCTGGTACTGCCAGTTGAATCTG	SARS-CoV-2, N gene	[3]
2019-nCoV_N1-P	FAM-ACCCCGCATTACGTTTGGTGGACC-BHQ1	SARS-CoV-2, N gene	[3]
2019-nCoV_N2-F	TTACAAACATTGGCCGCAAA	SARS-CoV-2, N gene	[3]
2019-nCoV_N2-R	GCGCGACATTCCGAAGAA	SARS-CoV-2, N gene	[3]
2019-nCoV_N2-P	FAM-ACAATTTGCCCCAGCGCTTCAG-BHQ1	SARS-CoV-2, N gene	[3]
Hs_RPP30-F	AGATTTGGACCTGCGAGCG	Human <i>RPP30</i>	[3]
Hs_RPP30-R	GAGCGGCTGTCTCCACAAGT	Human <i>RPP30</i>	[3]
HEX-Hs_RPP30-P	HEX-TTCTGACCTGAAGGCTCTGCGCG-BHQ1	Human <i>RPP30</i>	[3]
PhHV-F	GGGCGAATCACAGATTGAATC	PhHV-1, Glycoprotein B	[4]
PhHV-R**	GCGGTTCCAAACGTACCA(A)	PhHV-1, Glycoprotein B	[4]
Cy5-PhHV-P***	Quasar-670-TTTTTATGTGTCCGCCACCATCTGGATC-BHQ2	PhHV-1, Glycoprotein B	[4]

* Probe named TxRd for simplicity, CAL Flour Red (CFR-610) has virtually identical properties to TexRed

** Reverse primer GCGGTTCCAAACGTACCA used for our work; GCGGTTCCAAACGTACCAA used in [4]; both should work equally

*** Probe named Cy5 for simplicity. Quasar 670 has virtually identical properties to Cy5

Primer/Probe Mixes

Table P2. 50x N1 (FAM) Primer/Probe Mix

Oligonucleotide	Stock Concentration (μM)	Concentration in 50x mix (μM)	Concentration in reaction (nM)	Volume (μL)
2019-nCoV_N1-F	100	25	500	50
2019-nCoV_N1-R	100	25	500	50
2019-nCoV_N1-P	100	6.25	125	12.5
Nuclease free water	-	-	-	87.5
Total				200

Table P3. 50x N2 (FAM) Primer/Probe Mix

Oligonucleotide	Stock Concentration (μM)	Concentration in 50x mix (μM)	Concentration in reaction (nM)	Volume (μL)
2019-nCoV_N2-F	100	25	500	50
2019-nCoV_N2-R	100	25	500	50
2019-nCoV_N2-P	100	6.25	125	12.5
Nuclease free water	-	-	-	87.5
Total				200

Table P4. 50x E gene (TexRed) Primer/Probe Mix

Oligonucleotide	Stock Concentration (μM)	Concentration in 50x mix (μM)	Concentration in reaction (nM)	Volume (μL)
E_Sarbeco_F1	100	20	400	40
E_Sarbeco_R2	100	20	400	40
TxRd_E_Sarbeco_P1	100	10	200	20
Nuclease free water	-	-	-	100
Total				200

Supplement: An affordable multiplex RT-qPCR assay for SARS-CoV-2 detection July 14, 2020

Table P5. 50x RPP30 (HEX) Primer/Probe Mix

Oligonucleotide	Stock Concentration (μM)	Concentration in 50x mix (μM)	Concentration in reaction (nM)	Volume (μL)
Hs_RPP30-F	100	25	500	50
Hs_RPP30-R	100	25	500	50
HEX-Hs_RPP30-P	100	6.25	125	12.5
Nuclease free water	-	-	-	87.5
Total				200

Table P6. 50x PhHV (Cy5) Primer/Probe Mix

Oligonucleotide	Stock Concentration (μM)	Concentration in 50x mix (μM)	Concentration in reaction (nM)	Volume (μL)
PhHV-F	100	15	300	30
PhHV-R	100	15	300	30
Cy5-PhHV-P	100	5	100	10
Nuclease free water	-	-	-	130
Total				200

Table P7. 12.5x 4-plex Primer/Probe Mix (for 100 reactions)

	Stock	Probe Concentration in 12.5x mix (μM)	Probe Concentration in reaction (nM)	Volume (μL)
N1 or N2 mix (FAM)	50x	1.56	125	50
E mix (TxRed)	50x	2.5	200	50
RPP30 mix (HEX)	50x	1.56	125	50
PhHV mix (Cy5)	50x	1.25	100	50
Total				200

Supplement: An affordable multiplex RT-qPCR assay for SARS-CoV-2 detection July 14, 2020

RT-qPCR

Any Real-Time qPCR machine that can detect the four different channels and has been calibrated for the appropriate fluorophores can be used. We use the Applied Biosystems™ 7500 Fast Real-Time PCR Systems (channels FAM, JOE, TEXAS RED and CY5) and 7500 Software v2.3, MicroAmp Fast Optical 0.1mL 96-well reaction plates (Cat. No. 4346906) and Optical Adhesive film (Cat. No. 4311971). We performed all RT-qPCRs with Takara One Step PrimeScript™ III RT-qPCR kit (Cat. No. RR600B). Other One-Step mixes are available, but may require slightly different reaction conditions and may change sensitivity of SARS-CoV-2 detection.

N1E-RP and N2E-RP 4-plex assay

Master Mix (20 µl per reaction), assemble on ice

H2O (RNase free)	5.5 µl	for 100x	550 µl
2x Reaction mix	12.5 µl		1250 µl
12.5x primer/probe mix	2 µl		200 µl
Mix with template RNA	5 µl		

Spin down before transferring to PCR machine

PCR program

52°C	5 min (reverse transcription)
95°C	10 s (RT inactivation/denaturation)
45 cycles of	95°C 3 s (denaturation)
	60°C 30 s (amplification & detection)

Controls

Add the viral spike-in control to the lysis buffer master mix before sample inactivation.

Supplement: An affordable multiplex RT-qPCR assay for SARS-CoV-2 detection July 14, 2020

[For our assays, we used 25 μ l of culture supernatant containing PhHV particles to 25 ml of lysis buffer. This amount was previously shown to give a Ct value of ~33.]

For each plate, include the following controls,

H10: negative extraction control, VTM extracted

H11: non-extraction negative control, water only

H12: 50 copies of positive control RNA (see below)

Positive control RNA

Positive control RNAs generated by in vitro transcription (IVT) were provided by:

- Sylvie Behillil (Institut Pasteur, Paris, France): mix of E gene and RdRp (the latter is not the same as the Corman et al (2020) RdRp template) [1-3] at 10^9 copies/ μ l

- Christine Tait-Burkard (Roslin Institute, Edinburgh, UK): RdRp [1, 2], N1/N3 and N2 [3]. Three individual IVT RNAs at known concentrations (ng/ μ l) were provided; molecular weights used to determine the concentrations in copies/ μ l and 10^9 copies/ μ l prepared for each RNA.

Prepare all stocks and dilutions in Eppendorf DNA LoBind tubes (Cat. No. 10051232).

1. Prepare an equimolar mix of all RNAs at 2.5×10^8 copies/ μ l. Store aliquots of this solution at -80°C .

2. Prepare 10^4 copies/ μ l positive RNA controls and store 5 μ l aliquots at -80°C for single use per plate. Mix 5 μ l of 2.5×10^8 copies/ μ l with 620 μ l of water to give 2×10^6 copies/ μ l. Dilute this 20 μ l plus 180 μ l water giving a 2×10^5 copies/ μ l solution, and 20 μ l plus 380 μ l giving 10^4 copies/ μ l.

3. For each plate, a 25 copies/ μ l solution is made by diluting the 10^4 copies/ μ l solution by mixing:

2 μ l with 98 μ l water, then

12.5 μ l of this with 87.5 μ l water

Of this 25 copies/ μ l solution, 2 μ l is added to well H12 along with 3 μ l of water, to give the 50 copy positive control on each plate.

Supplementary Protocol 2: Viral nucleic acid isolation

In principle, the buffers and solution below can replace those of the equivalent buffers in the Omega Mag-Bind Viral DNA/RNA 96 Kit (Cat. No. M6246). Lysis and wash buffers can either be replaced with guanidine thiocyanate (GnSCN) or guanidine hydrochloride (GnHCl) containing solutions, depending on reagent availability. In our preliminary tests, all performed equally well (data not shown). All lysis buffers (Omega TNA, GnSCN Lysis Buffer, GnHCl Lysis Buffer, each with/without isopropanol) were shown to inactivate coronavirus after 15 min incubation (Fig S4). Briefly, to determine whether lysis buffers inactivate coronaviruses, 200 μ l CoV 229E-GFP [5, 6] stock (9.6×10^5 pfu/ml in DMEM, 10% FCS, 1% NEAA) was mixed with lysis buffer at the recommended ratio (240 μ l lysis buffer without isopropanol or 520 μ l lysis buffer with isopropanol, i.e. 240 μ l buffer and 280 μ l isopropanol). For positive infection controls, virus was mixed with 240 or 520 μ l medium. All mixes were inverted 8 times and incubated at room temperature for 15 min. Cytotoxic components were then removed by centrifugation at 4°C using Microcon filter columns (Millipore; 30 kDa cut-off), and two 0.5 ml PBS washes, similar to previously described methods [7, 8]. Remaining virus particles were then resuspended in 200 μ l DMEM and 50 μ l of a 1/100 dilution added to HUH7 cells (a cell line permissive to infection by CoV 229E). Cells were seeded the previous day at 1.8×10^4 /well in a black 96-well plate (Corning), and were at ~80% confluence for infection. Cultures were monitored daily for cell viability, cytopathic effects and GFP expression using microscopy. No significant cell death was observed for any of the samples. Relative fluorescence was measured using a Clariostar BMG Plate Reader at 72 h, with fluorescence for a non-infected control set to zero. No fluorescence was observed for any of the lysis buffer treated samples (Fig S4), and fluorescence microscopy confirmed the absence of GFP positive cells (data not shown), consistent with complete viral inactivation.

In our preliminary tests, we used the March 2020 version of the protocol provided with the Omega Mag-Bind Viral DNA/RNA 96 Kit to test viral nucleic acid isolation with our own solutions and reagents (see below). We used the Mag-Bind Particles CNR from the Omega kit, and although we have not yet tested this, we expect that these can be replaced by SeraSil-Mag silica beads (Cytiva, cat No. 29357375). The March 2020 protocol is different from the April 2020 Supplementary Protocol provided by Omega. The latter was used in combination with original Omega kit components for all other work presented in our manuscript. We do not see any reasons why our solutions would not work equally well with the April 2020 version of the protocol, but have not tested this. All purifications were carried out using a KingFisher Flex robot (Cat. No. 5400610), KingFisher Deep well plates (Cat. No. 95040450), KingFisher Flex 96 Deep-Well Tip Combs (Cat. No.

Supplement: An affordable multiplex RT-qPCR assay for SARS-CoV-2 detection July 14, 2020

A43074) and KingFisher 96 microplates (Cat. No. 97002540). Alternative robots could be used; and manual purifications are also possible.




Figure S4. Inactivation of coronavirus CoV-229E by Omega TNA, and GnSCN and GnHCl lysis buffers. CoV 229E-GFP was mixed with lysis buffer (- or + isopropanol) as described and then used to infect HUH7 cells. After 72 h of infection, GFP fluorescence (indicating infected cells) was measured. Negative (neg) control, no infection; positive control (Pos1 and 2), virus mixed with medium instead of lysis buffer. Fluorescence units (RFU) are expressed relative to background (negative control fluorescence set to 0). Solid lines indicate the mean for n=2 independent experiments.

Protocol in brief (tested with home-made solutions; based on Omega March 2020 protocol)

1. Per sample, prepare 528 μ l master mix: 240 μ l lysis buffer, 8 μ l carrier RNA (1 μ g/ μ l) and 280 μ l isopropanol
2. Add 200 μ l of patient sample in VTM, mix thoroughly; incubate for >15 min
3. Add 20 μ l of 1:1 mix of Magnetic bead suspension and Proteinase K solution (40 μ g/ μ l). KingFisher Flex, loop though 3 times: 2 min fast mix, 30 s half mix, 30 s bottom mix
4. Employ magnetic separation (Collect beads, 3x10 s)
5. Wash beads with 400 μ L VHB wash buffer (Release beads, 3 min fast mix, collect beads 3x5 s)
6. Wash beads with 500 μ L SPR Wash buffer (Release beads, 2 min fast mix, collect beads 3x5 s)
7. Wash beads with 500 μ L SPR Wash buffer (Release beads, 2 min fast mix, collect beads 3x5 s)
8. Air dry magnetic beads (10 min, above well)
9. Elute nucleic acids in 50 μ l nuclease-free water (Release beads, 5 min medium mix, collect beads 3x10 s)

Protocol in brief (not tested with home-made solutions; based on Omega April 2020 protocol)

1. Per sample, mix 240 μ l lysis buffer and 1 μ l carrier RNA (1 μ g/ μ l)
2. Add 200 μ l of patient sample in VTM, mix thoroughly; incubate for >15 min
3. Add isopropanol bead mix (280 μ l isopropanol and 2 μ l magnetic beads). KingFisher Flex, loop though 3 times: 2 min fast mix, 30 s half mix, 30 s bottom mix
4. Employ magnetic separation (Collect beads, 3x10 s)
5. Wash beads with 350 μ L VHB wash buffer (Release beads, 3 min fast mix, collect beads 3x5 s)
6. Wash beads with 350 μ L SPR Wash buffer (Release beads, 2 min fast mix, collect beads 3x5 s)
7. Wash beads with 350 μ L SPR Wash buffer (Release beads, 2 min fast mix, collect beads 3x5 s)
8. Air dry magnetic beads (10 min, above well)
9. Elute nucleic acids in 50 μ l nuclease-free water (Release beads, 5 min medium mix, collect beads 3x10 s)

Reagents

Guanidine thiocyanate based

GnSCN Lysis Buffer (TNA Lysis buffer equivalent)

	Amount for 1 L	Concentration
Guanidine thiocyanate	473 g	4 M
Sarkosyl (sodium lauroyl sarcosinate)	20 g	2%
1 M Tris-HCl pH 7.5	50 ml	50 mM
0.5 M EDTA pH 8.0	20 ml	10 mM
β -mercaptoethanol	10 ml	1%

GnSCN Wash buffer 1 (VHB Wash buffer equivalent)

	Amount for 1 L	Concentration
Guanidine thiocyanate	118 g	1 M
1 M Sodium citrate pH 7*	10 ml	10 mM
Ethanol	560 ml	56%

*to set pH, add 10 ml 1 M HCl for every 500 ml 1 M Sodium citrate.

Guanidine hydrochloride based

GnHCl Lysis Buffer (TNA Lysis buffer equivalent)

	Amount for 1 L	Concentration
Guanidine hydrochloride	573 g	6 M
Sarkosyl (sodium lauroyl sarcosinate)	20 g	2%
1 M Tris-HCl pH 7.5	50 ml	50 mM
0.5 M EDTA pH 8.0	20 ml	10 mM
β -mercaptoethanol	10 ml	1%

GnHCl Wash Buffer 1 (VHB Wash buffer equivalent)

	Amount for 1 L	Concentration
Guanidine hydrochloride	107 g	1.25 M
1 M Sodium citrate pH 7*	10 ml	10 mM
Ethanol	560 ml	56%

*to set pH, add 10 ml 1 M HCl for every 500 ml 1 M Sodium citrate.

SPR Wash buffer 2 equivalent

80% Ethanol

Proteinase K (PCR grade; e.g. Roche Cat. No. 03115801001)

Dissolve in 10 mM Tris pH 8.0, 1 mM EDTA at 40 mg/ml

Store aliquots at -20°C

Carrier RNA (e.g. yeast tRNA, Roche Cat. No. 10109509001)

Dissolve in 10 mM Tris pH 8.0, 1 mM EDTA at 1 mg/ml

Store aliquots at -20°C

Supplementary references

1. Corman et al (2020) COVID-19 RT-qPCR protocol v2 Available from: <https://www.who.int/docs/default-source/coronaviruse/protocol-v2-1.pdf>.
2. Corman VM, Landt O, Kaiser M, Molenkamp R, Meijer A, Chu DK, et al. Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. *Euro Surveill.* 2020;25(3). Epub 2020/01/30. doi: 10.2807/1560-7917.ES.2020.25.3.2000045. PubMed PMID: 31992387; PubMed Central PMCID: PMC6988269.
3. WHO in-house assays COVID-19 RT-qPCR. Available from: https://www.who.int/docs/default-source/coronaviruse/whoinhouseassays.pdf?sfvrsn=de3a76aa_2.
4. Stranska R, Schuurman R, de Vos M, van Loon AM. Routine use of a highly automated and internally controlled real-time PCR assay for the diagnosis of herpes simplex and varicella-zoster virus infections. *J Clin Virol.* 2004;30(1):39-44. Epub 2004/04/10. doi: 10.1016/j.jcv.2003.08.006. PubMed PMID: 15072752.
5. Cervantes-Barragan L, Zust R, Maier R, Sierro S, Janda J, Levy F, et al. Dendritic cell-specific antigen delivery by coronavirus vaccine vectors induces long-lasting protective antiviral and antitumor immunity. *mBio.* 2010;1(4). Epub 2010/09/17. doi: 10.1128/mBio.00171-10. PubMed PMID: 20844609; PubMed Central PMCID: PMC2939679.
6. Thiel V, Siddell SG. Reverse genetics of coronaviruses using vaccinia virus vectors. *Curr Top Microbiol Immunol.* 2005;287:199-227. Epub 2004/12/22. doi: 10.1007/3-540-26765-4_7. PubMed PMID: 15609513.
7. Burton JE, Easterbrook L, Pitman J, Anderson D, Roddy S, Bailey D, et al. The effect of a non-denaturing detergent and a guanidinium-based inactivation agent on the viability of Ebola virus in mock clinical serum samples. *J Virol Methods.* 2017;250:34-40. Epub 2017/09/25. doi: 10.1016/j.jviromet.2017.09.020. PubMed PMID: 28941617.
8. Pastorino B, Touret F, Gilles M, de Lamballerie X, Charrel RN. Evaluation of heating and chemical protocols for inactivating SARS-CoV-2. 2020:2020.04.11.036855. doi: 10.1101/2020.04.11.036855 %J bioRxiv.